TrialClinical drug investigation2013

Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.

Rajendra H Jani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.